Cargando…
Acquired Resistance to Antibody-Drug Conjugates
Antibody-drug conjugates (ADCs) combine the tumor selectivity of antibodies with the potency of cytotoxic small molecules thereby constituting antibody-mediated chemotherapy. As this inherently limits the adverse effects of the chemotherapeutic, such approaches are heavily pursued by pharma and biot...
Autores principales: | Collins, Denis M., Bossenmaier, Birgit, Kollmorgen, Gwendlyn, Niederfellner, Gerhard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468698/ https://www.ncbi.nlm.nih.gov/pubmed/30897808 http://dx.doi.org/10.3390/cancers11030394 |
Ejemplares similares
-
Structural Requirements for Cub Domain Containing Protein 1 (CDCP1) and Src Dependent Cell Transformation
por: Kollmorgen, Gwendlyn, et al.
Publicado: (2012) -
Combining anti-CTLA4 with RG7787, an immunotoxin targeting mesothelin, promotes tumor eradication
por: Leshem, Jasmin, et al.
Publicado: (2015) -
Mechanisms of Resistance to Antibody–Drug Conjugates
por: Abelman, Rachel Occhiogrosso, et al.
Publicado: (2023) -
Mechanisms of Resistance to Antibody-Drug Conjugates
por: Khoury, Rita, et al.
Publicado: (2023) -
A re-engineered immunotoxin shows promising preclinical activity in ovarian cancer
por: Kollmorgen, Gwendlyn, et al.
Publicado: (2017)